Viewing data from:

ALLZITAL

ANDA

ACETAMINOPHEN; BUTALBITAL | A203484 | PHARMOBEDIENT CONSULTING LLC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Allzital (2023)

Total Spending

$3K

Total Claims

Beneficiaries

Avg Cost/Unit

$4.03

Spending Trend

$8K(2021)→$8K(2022)→$3K(2023)

YoY Change:+3.3%

5yr CAGR:-2.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (2)

Sort:

#001 — 325MG;25MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Dec 4, 2015

No patent or exclusivity listings for this strength.

#002 — 325MG;50MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Dec 4, 2015